The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2017 | Venetoclax in combination with antibodies in the treatment of CLL
John Gribben, MD, DSc, FRCPath, FMed Sci from Barts Cancer Institute, London, UK discusses the use of venetoclax in combination with antibodies in the treatment of CLL at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. Venetoclax is commonly used as a monotherapy, and has been shown to eradicate minimal residual disease in relapsed and refractory patients. Combining venetoclax with other drugs, for example, ibrutinib, rituximab or obinutuzumab, potentially may drive patients into deep remissions, where therapy can be stopped altogether. Multiple studies are currently investigating this combination, in Germany, Australia, and the CLARITY study (NCT03128879) in the UK. Although combining the treatments may multiply the cost, the end result of driving patients into deep remissions will be cost effective, and the main goal of therapy. This video has been supported by Napp Pharmaceuticals Ltd through an unrestricted educational grant to Magdalen Medical Publishing.
